68Ga-N188 PET/CT Imaging in Malignancy

Recruiting now · Not applicable

Conditions studied: Neoplasms

In brief

The Nectin-4 protein belongs to the cell adhesion factors family and has a tissue-specific expression spectrum in normal human tissues. However, Nectin-4 is overexpressed in various malignancies, especially those of epithelial origins, such as uroepithelial carcinoma, making Nectin-4 a highly specific and significant imaging target for malignancies. \[68Ga\]N188, a novel molecular probe of PET imaging agent that targets Nectin-4, can be used in the diagnosis and research of a wide variety of Nectin-4 high-expression malignancies, including bladder cancer.

Key facts

Study ID

NCT05593107

Run by

Peking University First Hospital

People needed

203

Starts

2022-08-12

Expected to finish

2025-07-31

Last updated by the study team

2024-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• patients with confirmed or suspected cancer;
• 18F-FDG PET/CT within 1 week;
• Signed written informed consent.

You may not qualify if…

• Pregnant and lactating women;
• Female patients plan to become pregnant within 6 months.

Where it is running

• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.